Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.
公司代碼RGNT
公司Regentis Biomaterials Ord Shs
CEOHazum (Eli)
網址https://www.regentis.co.il/
常見問題
Regentis Biomaterials Ord Shs(RGNT)的當前股價是多少?
Regentis Biomaterials Ord Shs(RGNT)的當前股價是 7.140。
Regentis Biomaterials Ord Shs 的股票代碼是什麼?
Regentis Biomaterials Ord Shs的股票代碼是RGNT。
Regentis Biomaterials Ord Shs股票的52週最高點是多少?
Regentis Biomaterials Ord Shs股票的52週最高點是7.698。
Regentis Biomaterials Ord Shs股票的52週最低點是多少?
Regentis Biomaterials Ord Shs股票的52週最低點是6.955。
Regentis Biomaterials Ord Shs的市值是多少?
Regentis Biomaterials Ord Shs的市值是--。
Regentis Biomaterials Ord Shs的淨利潤是多少?
Regentis Biomaterials Ord Shs的淨利潤為--。
現在Regentis Biomaterials Ord Shs(RGNT)的股票是買入、持有還是賣出?
根據分析師評級,Regentis Biomaterials Ord Shs(RGNT)的總體評級為--,目標價格為--。
Regentis Biomaterials Ord Shs(RGNT)股票的每股收益(EPS TTM)是多少
Regentis Biomaterials Ord Shs(RGNT)股票的每股收益(EPS TTM)是--。